pBI-4 Vaccine

Preclinical

pBI-4 Vaccine is one of 6 therapeutic programs targeting Cervical Intraepithelial Neoplasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cervical Intraepithelial NeoplasiaNot yet recruiting

Cervical Intraepithelial NeoplasiaPreclinical

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Cervical Intraepithelial Neoplasia

#DrugCompanyPhaseTrials

Taxol

Prometrium

Keytruda

1 4

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Phase 3

1 5

Tricor

JJagotec

Phase 1

1 6

pBI-4 Vaccine

CChang Gung Memorial Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalNot yet recruiting

Cervical Intraepithelial Neoplasia

NCT07809997

Clinical

Trials by Indication[1]

Cervical Intraepithelial Neoplasia1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of pBI-4 Plasmid Administered Via Intramuscular TriGrid™ Electroporation Delivery System for Treatment of Women With HPV16-Positive Grade 1 Cervical Intraepithelial Neoplasia or Persistent HPV16 Infection

Not yet recruiting·CChang Gung Memorial Hospital·Preclinical·NCT07809997·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pBI-4 Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for pBI-4 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Chang Gung Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CChang Gung Memorial Hospital

pBI-4 Vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Cervical Intraepithelial Neoplasia1 trial

References

Drug Info

Quick Facts

Related News